Crossmark

BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes

Crossref DOI link: https://doi.org/10.1186/s40425-019-0744-4

Published Online: 2019-11-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Yu-Li

Lin, Han-Wei

Chien, Chung-Liang

Lai, Yen-Ling

Sun, Wei-Zen

Chen, Chi-An

Cheng, Wen-Fang https://orcid.org/0000-0002-3282-6304
Funding

Funding for this research was provided by:

Ministry of Science and Technology, Taiwan (MOST 107-2314-B-002-159 and 107-2314-B-002-155-MY3)

National Taiwan University Hospital (NTUH UN106-048 and 107-N3976)
License Information

Text and Data Mining valid from 2019-11-21
More Information

Article History

Received: 1 March 2019

Accepted: 20 September 2019

First Online: 21 November 2019

Ethics approval and consent to participate

: The research protocol and consent form were approved by the Institutional Review Boards of National Taiwan University Hospital (20076002R). All of the specimens were acquired after informed consent was signed.

: The manuscript was approved by all of the authors before submission.

: The authors declare that they have no competing interests.